A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

NCT00502567 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: AZD2171
DRUG: FOLFOX
DRUG: Pemetrexed
DRUG: Irinotecan (administered with & without Cetuximab)
DRUG: Docetaxel

Sponsor

AstraZeneca